Excessive collagen type VII mediates pleural fibrosis via increasing extracellular matrix stiffness.
Summary
Collagen VII is an early, upstream driver of pleural fibrosis. Mesothelial cell-specific Col7a1 deletion attenuated fibrosis, and excess collagen VII increased ECM stiffness to activate integrin/PI3K‑AKT/JUN signaling and feed-forward matrix deposition.
Key Findings
- Collagen VII is increased in human tuberculous pleural fibrosis and rises early in experimental models before collagen I and α‑SMA.
- Mesothelial cell-specific Col7a1 deletion (WT1‑Cre+; COL7A1flox/flox) attenuated pleural fibrosis in mice.
- Excess collagen VII increases ECM stiffness, activating integrin/PI3K‑AKT/JUN signaling and promoting further ECM deposition.
Clinical Implications
Collagen VII may serve as an early biomarker and therapeutic target; integrin/PI3K‑AKT pathway inhibition or stiffness-modulating strategies could be explored for pleural fibrosis.
Why It Matters
Identifies a mechanobiologic pathway (collagen VII→ECM stiffness→integrin signaling) as a tractable target for pleural fibrosis, shifting focus beyond collagen I/myofibroblasts.
Limitations
- Human data primarily from tuberculous pleural fibrosis; generalizability to other etiologies needs confirmation.
- No clinical interventional trials; translation of stiffness-targeting strategies remains to be tested in patients.
Future Directions
Validate collagen VII as a biomarker across pleural fibrosis etiologies; test integrin/PI3K‑AKT/JUN inhibitors and stiffness-modulating therapies in preclinical models and early-phase trials.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- IV - Mechanistic studies in human tissues, cell systems, and conditional knockout mice without randomized clinical testing.
- Study Design
- OTHER